Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 6.6a

Immunosuppression Use for Induction, 2000 to 2009

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Year of Transplant
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Transplants 134 168 180 160 183 199 174 210 223 181
With Immunosuppression Info 128 165 176 154 179 193 168 201 219 174
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 0.0% 0.0% 0.0% 1.3% 2.2% 0.0% 0.6% 1.0% 1.4% 1.7%
OKT3 4.7% 3.0% 3.4% 0.6% 0.0% 2.1% 5.4% 7.5% 6.4% 13.2%
Thymoglobulin 48.4% 49.1% 60.8% 45.5% 50.3% 48.2% 41.7% 41.3% 49.8% 59.2%
Zenapax 44.5% 34.5% 31.3% 8.4% 9.5% 5.2% 10.7% 7.0% 6.8% 2.9%
Simulect 9.4% 3.0% 4.0% 6.5% 0.0% 2.1% 2.4% 3.5% 4.6% 4.0%
Campath 0.0% 0.0% 1.1% 31.2% 41.3% 33.7% 23.8% 13.9% 11.4% 12.6%
No Induction Drugs Recorded 29.7% 38.8% 29.5% 18.2% 20.1% 16.6% 21.4% 33.8% 26.9% 21.8%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.